Catalysts / LXEO
Upcoming FDA decisions and readouts we track for Lexeo Therapeutics, each with the filing that announced it.
FreeBioList tracks 3 upcoming catalysts for Lexeo Therapeutics (LXEO, listed on Nasdaq). They cover 2 programmes: LX2020 (PKP2 arrhythmogenic cardiomyopathy (gene therapy)) and LX2006 (Friedreich ataxia cardiomyopathy (gene therapy); Friedreich ataxia cardiomyopathy).
First on the list: the Phase 1/2 readout for LX2020 (PKP2 arrhythmogenic cardiomyopathy (gene therapy)), guided by the company to Q4 2026. The furthest-out event tracked is H1 2028. By stage, the upcoming rows are 2 Phase 1/2 readouts and 1 Regulatory submission.
All 3 rows link to SEC filings (8-K or 6-K). All have been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.
Background reading: Clinical trial phases explained: Phase 1 to Phase 4; NDA vs BLA: the two kinds of US drug application.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Lexeo Therapeutics LXEO · Nasdaq | LX2020 | PKP2 arrhythmogenic cardiomyopathy (gene therapy) | Q4 2026 company guidance |
Phase 1/2 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
| Lexeo Therapeutics LXEO · Nasdaq | LX2006 | Friedreich ataxia cardiomyopathy (gene therapy) | H2 2027 company guidance |
Phase 1/2 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
| Lexeo Therapeutics LXEO · Nasdaq | LX2006 | Friedreich ataxia cardiomyopathy | H1 2028 company guidance |
Regulatory submission | Verified | 8-K exhibit 99.1 ↗ | Yes |
FreeBioList